Display options
Cite
Pérez-Segura P, Paz-Cabezas M, Núñez-Gil IJ, et al. Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data. Med Clin (Barc). 2021;157(7):318-324doi: 10.1016/j.medcli.2021.02.021.
Pérez-Segura, P., Paz-Cabezas, M., Núñez-Gil, I. J., Arroyo-Espliguero, R., Maroun Eid, C., Romero, R., Fernández Rozas, I., Uribarri, A., Becerra-Muñoz, V. M., García Aguado, M., Huang, J., Rondano, E., Cerrato, E., Rodríguez, E. A., Ortega-Armas, M. E., Raposeiras Roubin, S., Pepe, M., Feltes, G., Gonzalez, A., Cortese, B., Buzón, L., El-Battrawy, I., & Estrada, V. (2021). Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data. Medicina clinica, 157(7), 318-324. https://doi.org/10.1016/j.medcli.2021.02.021
Pérez-Segura, Pedro, et al. "Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data." Medicina clinica vol. 157,7 (2021): 318-324. doi: https://doi.org/10.1016/j.medcli.2021.02.021
Pérez-Segura P, Paz-Cabezas M, Núñez-Gil IJ, Arroyo-Espliguero R, Maroun Eid C, Romero R, Fernández Rozas I, Uribarri A, Becerra-Muñoz VM, García Aguado M, Huang J, Rondano E, Cerrato E, Rodríguez EA, Ortega-Armas ME, Raposeiras Roubin S, Pepe M, Feltes G, Gonzalez A, Cortese B, Buzón L, El-Battrawy I, Estrada V. Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data. Med Clin (Barc). 2021 Oct 08;157(7):318-324. doi: 10.1016/j.medcli.2021.02.021. Epub 2021 May 06. Spanish. PMID: 34154809; PMCID: PMC8101784.
Copy Download .nbib Format: NLM
Share it on

Med Clin (Barc). 2021 Oct 08;157(7):318-324. doi: 10.1016/j.medcli.2021.02.021. Epub 2021 May 06.

Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data.

Medicina clinica

[Article in Spanish]
Pedro Pérez-Segura, M Paz-Cabezas, I J Núñez-Gil, R Arroyo-Espliguero, C Maroun Eid, R Romero, I Fernández Rozas, A Uribarri, V M Becerra-Muñoz, M García Aguado, J Huang, E Rondano, E Cerrato, E Alfonso Rodríguez, M E Ortega-Armas, S Raposeiras Roubin, M Pepe, G Feltes, A Gonzalez, B Cortese, L Buzón, I El-Battrawy, V Estrada

Affiliations

  1. Medical Oncology Dpt. Hospital Clinico San Carlos, Madrid, Spain. Electronic address: [email protected].
  2. Medical Oncology Dpt. Hospital Clinico San Carlos, Madrid, Spain.
  3. Hospital Clinico San Carlos, Madrid, Spain.
  4. Hospital Universitario Guadalajara, Guadalajara, Spain.
  5. Hospital Universitario La Paz. Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Madrid, Spain.
  6. Hospital Universitario Getafe, Madrid, Spain.
  7. Hospital Universitario Severo Ochoa, Leganés, Spain.
  8. Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
  9. Hospital Clinico Universitario Virgen de la Victoria, Málaga, Spain.
  10. Hospital Puerta de Hierro de Majadahonda. Majadahonda, Madrid, Spain.
  11. The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
  12. Sant'Andrea Hospital, Vercelli, Italy.
  13. San Luigi Gonzaga University Hospital, Orbassano and Rivoli Infermi Hospital, Rivoli, Turin, Italy.
  14. Institute of Cardiology and Cardiovascular Surgery, Havana, Cuba.
  15. Hospital General del Norte de Guayaquil IESS Los Ceibos, Guayaquil, Ecuador.
  16. University Hospital Alvaro Cunqueiro, Vigo, Spain.
  17. Azienda ospedaliero-universitaria consorziale policlinico di Bari, Bari, Italy.
  18. Nuestra Señora de América, Madrid, Spain.
  19. Hospital Universitario Infanta Sofia. San Sebastian de los Reyes, Madrid, Spain.
  20. San Carlo Clinic, Milano, Italy.
  21. Hospital Universitario de Burgos, Burgos, Spain.
  22. First Department of Medicine, Medical Faculty Mannheim, University Heidelberg, Mannheim, 68167, Germany, DZHK (German Center for Cardiovascular Research), Partner Site, Heidelberg-Mannheim, Mannheim, Germany.

PMID: 34154809 PMCID: PMC8101784 DOI: 10.1016/j.medcli.2021.02.021

Abstract

BACKGROUND: Previous works seem to agree in the higher mortality of cancer patients with COVID-19. Identifying potential prognostic factors upon admission could help identify patients with a poor prognosis.

METHODS: We aimed to explore the characteristics and evolution of COVID-19 cancer patients admitted to hospital in a multicenter international registry (HOPE COVID-19). Our primary objective is to define those characteristics that allow us to identify cancer patients with a worse prognosis (mortality within 30 days after the diagnosis of COVID-19).

RESULTS: 5838 patients have been collected in this registry, of whom 770 had cancer among their antecedents. In hospital mortality reached 258 patients (33.51%). The median was 75 years (65-82). Regarding the distribution by sex, 34.55% of the patients (266/770) were women. The distribution by type of cancer: genitourinary 238/745 (31.95%), digestive 124/745 (16.54%), hematologic 95/745 (12.75%). In multivariate regression analysis, factors that are independently associated with mortality at admission are: renal impairment (OR 3.45, CI 97.5% 1.85-6.58), heart disease (2.32, 1.47-3.66), liver disease (4.69, 1.94-11.62), partial dependence (2.41, 1.34-4.33), total dependence (7.21, 2.60-21.82), fatigue (1.84, 1.16-2.93), arthromialgias (0.45, 0.26-0.78), SatO2<92% (4.58, 2.97-7.17), elevated LDH (2.61, 1.51-4.69) and abnormal decreased Blood Pressure (3.57, 1.81-7.15). Analitical parameters are also significant altered.

CONCLUSION: In patients with cancer from the HOPE registry, 30-day mortality from any cause is high and is associated with easily identifiable clinical factors upon arrival at the hospital. Identifying these patients can help initiate more intensive treatments from the start and evaluate the prognosis of these patients.

Copyright © 2021 Elsevier España, S.L.U. All rights reserved.

Keywords: Admission; COVID-19; COVID19; Cancer; Cáncer; Factores; Factors; Ingreso; Prognosis; Pronóstico

MeSH terms

Publication Types